UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.086

Sortiert nach

Nivolumab in NSCLC: latest evidence and clinical potential

Therapeutic Advances in Medical Oncology, 2015-03, Vol.7 (2), p.85-96

2015

Link zum Volltext

Verfügbarkeit prüfen

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2016-03, Vol.93, p.59-68

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in the treatment of non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.101-109

2014

Link zum Volltext

Verfügbarkeit prüfen

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset

Frontiers in oncology, 2023-03, Vol.13, p.1117348-1117348

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib

Journal of clinical oncology, 2007-06, Vol.25 (18), p.2528-2533

2007

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100332-100332, Article 100332

2022

Link zum Volltext

Verfügbarkeit prüfen

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

Cancer treatment reviews, 2018-04, Vol.65, p.1-10

2018

Link zum Volltext

Verfügbarkeit prüfen

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Nature medicine, 2015-06, Vol.21 (6), p.560-562

2015

Link zum Volltext

Verfügbarkeit prüfen

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1233-1243

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2019-12, Vol.105 (5), p.1065-1073

2019

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Experimental and Molecular Medicine, 2020, 52(0), , pp.1-14

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Afatinib as Third‐Line Treatment for Patients in Korea With Stage IIIB/IV Non‐Small Cell Lung Cancer Harboring Wild‐Type EGFR

The oncologist (Dayton, Ohio), 2014-07, Vol.19 (7), p.702-703

2014

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Lung cancer (Amsterdam, Netherlands), 2018-01, Vol.115, p.12-20

2018

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

European journal of cancer (1990), 2020-01, Vol.125, p.49-57

2020

Link zum Volltext

Verfügbarkeit prüfen

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2021-04, Vol.39 (11), p.1253-1263

2021

Link zum Volltext

Verfügbarkeit prüfen

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Cancer discovery, 2020-08, Vol.10 (8), p.1194-1209

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute

Journal of surgical oncology, 2007-05, Vol.95 (6), p.461-468

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Journal of clinical oncology, 2017-05, Vol.35 (13), p.1403-1410

2017

Link zum Volltext

Verfügbarkeit prüfen

Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1733-1744

2021

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1373-1382

2018

Link zum Volltext

Verfügbarkeit prüfen

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Link zum Volltext

Verfügbarkeit prüfen

Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer

The Annals of thoracic surgery, 2011-02, Vol.91 (2), p.344-348

2011

Link zum Volltext

Verfügbarkeit prüfen

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Clinical cancer research, 2021-08, Vol.27 (15), p.4397-4409

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.086

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(972)
Mit Volltextzugriff
(1.043)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(590)
Life Sciences & Biomedicine
(455)
Humans
(349)
Oncology
(251)
Female
(203)
Male
(200)
Middle Aged
(173)
Aged
(157)
Adult
(144)
Lung Neoplasms - Drug Therapy
(131)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(112)
Mutation
(112)
Physical Sciences
(99)
Lung Neoplasms - Genetics
(91)
Lung Cancer
(86)
Respiratory System
(84)
Lung Neoplasms - Pathology
(82)
Carcinoma, Non-Small-Cell Lung - Genetics
(81)
Tumors
(79)
Aged, 80 And Over
(77)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Nivolumab in NSCLC: latest evidence and clinical potential

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

Immunotherapy in the treatment of non-small cell lung cancer

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset

Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Phase II Study of Afatinib as Third‐Line Treatment for Patients in Korea With Stage IIIB/IV Non‐Small Cell Lung Cancer Harboring Wild‐Type EGFR

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study

Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Suchergebnisse filtern